Evaluation of nuclear factor κb and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610

BJU International

Volumn 108, Issue 2 B, 2011, Pages

  Okera, Meena ^a   Bae, Kyoungwha ^b   Bernstein, Eric ^c   Cheng, Liang ^d   Lawton, Colleen ^e   Wolkov, Harvey ^f   Pollack, Alan ^g   Dicker, Adam ^h   Sandler, Howard ⁱ   Sweeney, Christopher J ^j  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b RTOG Headquarters   (United States)

^c Providence Cancer Center   (United States)

^d INDIANA UNIVERSITY   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f Radiological Associates of Sacramento Medical Group Inc   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

CXCR4; Nf B; prostate cancer; radiation

Indexed keywords

ANDROGEN; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NF-KAPPA B; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES;

EID: 79960107662     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09884.x     Document Type: Article

References (29)

1. Baeuerle PA, Henkel T,. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-79
2. Garcia-Pineres AJ, Castro V, Mora G, et al,. Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 2001; 276: 39713-20
3. Guzman ML, Rossi RM, Karnischky L, et al,. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105: 4163-9 (Pubitemid 40720758)
4. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr,. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3629-39 (Pubitemid 27281838)
5. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD,. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389-94 (Pubitemid 30032121)
6. Sweeney C, Li L, Shanmugam R, et al,. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004; 10: 5501-7 (Pubitemid 39100488)
7. Zhang L, Altuwaijri S, Deng F, et al,. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 2009; 175: 489-99
8. Wang CY, Mayo MW, Baldwin AS Jr,. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-7 (Pubitemid 26398259)
9. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G,. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999; 96: 9136-41 (Pubitemid 29374720)
10. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C,. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-7 (Pubitemid 29108753)
11. Jones PL, Ping D, Boss JM,. Tumor necrosis factor alpha and interleukin-1beta regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EBP-beta and NF-kappaB. Mol Cell Biol 1997; 17: 6970-81 (Pubitemid 27505927)
12. Catz SD, Johnson JL,. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001; 20: 7342-51 (Pubitemid 33078205)
13. Muenchen HJ, Lin DL, Walsh MA, Keller ET, Pienta KJ,. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha 'super-repressor'. Clin Cancer Res 2000; 6: 1969-77 (Pubitemid 30305096)
14. Gupta S, Afaq F, Mukhtar H,. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 2002; 21: 3727-38 (Pubitemid 34620536)
15. Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, et al,. Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate 2006; 66: 1498-511 (Pubitemid 44465816)
16. Jin RJ, Lho Y, Connelly L, et al,. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68: 6762-9
17. Min J, Zaslavsky A, Fedele G, et al,. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16: 286-94
18. Dreicer R, Petrylak D, Agus D, Webb I, Roth B,. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007; 13: 1208-15 (Pubitemid 46424062)
19. Papandreou CN, Daliani DD, Nix D, et al,. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-21 (Pubitemid 41095144)
20. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H,. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 2008; 99: 539-42 (Pubitemid 351228571)
21. Porvasnik S, Sakamoto N, Kusmartsev S, et al,. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009; 69: 1460-9
22. Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F,. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther 2009; 8: 1893-905
23. Liang Z, Wu H, Reddy S, et al,. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 2007; 363: 542-6 (Pubitemid 47513664)
24. Roach M 3rd, Bae K, Speight J, et al,. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term Results: of RTOG 8610. J Clin Oncol 2008; 26: 585-91 (Pubitemid 351264352)
25. Hart CA, Brown M, Bagley S, Sharrard M, Clarke NW,. Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer 2005; 92: 503-12 (Pubitemid 40395531)
26. Tang CH, Tan TW, Fu WM, Yang RS,. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 2008; 29: 35-43
27. Scupoli MT, Donadelli M, Cioffi F, et al,. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica 2008; 93: 524-32 (Pubitemid 351536380)
28. Biswas DK, Cruz AP, Gansberger E, Pardee AB,. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000; 97: 8542-7 (Pubitemid 30639709)
29. Bancroft CC, Chen Z, Yeh J, et al,. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002; 99: 538-48 (Pubitemid 34461606)